Literature DB >> 2597198

Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice.

E Rapaport1, J Fontaine.   

Abstract

Intraperitoneal injections of adenosine 5'-monophosphate (AMP) or adenosine 5'-triphosphate (ATP), but not of adenosine, inorganic phosphate or pyrophosphate, were shown to inhibit tumor growth and host weight loss in tumor-bearing murine hosts. The inhibition of tumor growth and host weight loss did not exhibit a cause-effect relationship, though both were mediated through expansion of red blood cell (RBC) ATP pools which were promoted by administered adenine nucleotides. We then demonstrated that expansion of RBC ATP pools was preceded by expansion of liver ATP pools and that the adenosine precursor for this type of enhanced RBC ATP synthesis originated in the turnover of expanded liver ATP pools. Although adenosine, which is the primary catabolic product of ATP in the peritoneal cavity or the systemic circulation, was sufficient to yield an expansion of mouse liver ATP pools in vivo, external phosphate was required for the subsequent expansion of RBC ATP pools, which in turn produced elevated extracellular (blood plasma) ATP levels. The anticancer activities which correlate with the elevated blood plasma ATP concentrations are proposed to be the result of direct action of extracellular ATP on the tumor and host tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597198     DOI: 10.1016/0006-2952(89)90524-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Inhibitory effects of extracellular adenosine triphosphate on growth of esophageal carcinoma cells.

Authors:  Ming-Xia Wang; Lei-Ming Ren; Bao-En Shan
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 3.  Adenosine triphosphate: established and potential clinical applications.

Authors:  H J Agteresch; P C Dagnelie; J W van den Berg; J H Wilson
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

4.  Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines.

Authors:  Eliezer Rapaport; Anna Salikhova; Edward H Abraham
Journal:  Purinergic Signal       Date:  2015-04-29       Impact factor: 3.765

Review 5.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

6.  Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP.

Authors:  M C Lasso de la Vega; P Terradez; E Obrador; J Navarro; J A Pellicer; J M Estrela
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

7.  An in vivo model of melanoma: treatment with ATP.

Authors:  Nicholas White; Gillian E Knight; Peter E M Butler; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2009-04-04       Impact factor: 3.765

8.  P2X7 receptor as a novel drug delivery system to increase the entrance of hydrophilic drugs into cells during photodynamic therapy.

Authors:  Paulo Anastácio Furtado Pacheco; Leonardo Braga Gomes Ferreira; Leonardo Mendonça; Dinarte Neto M Ferreira; Juliana Pimenta Salles; Robson Xavier Faria; Pedro Celso Nogueira Teixeira; Luiz Anastacio Alves
Journal:  J Bioenerg Biomembr       Date:  2016-07-15       Impact factor: 2.945

9.  Exogenous adenosine 5'-triphosphate does not improve survival in rats with acute liver failure.

Authors:  Erin P Becker; DongFeng Sun; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 10.  P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Authors:  Lucas T Woods; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Gary A Weisman
Journal:  Biochem Pharmacol       Date:  2021-01-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.